All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Durect Corp., better known as a drug delivery firm, disclosed a successful phase I trial with DUR-928, described as an endogenous small-molecule new chemical entity that could work in metabolic diseases such as nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), as well as acute kidney injury.